View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
MONDAY, Aug. 16 (HealthDay News) -- The ella (ulipristal acetate) emergency contraceptive has been approved by the U.S. Food and Drug Administration. It's been available in Europe for more than a year under the brand name ellaOne.
To be taken within five days of contraceptive failure or unprotected intercourse, the drug is not meant to be used as a routine contraceptive, according to the FDA. Ella's safety and effectiveness were demonstrated in studies conducted in the United States, United Kingdom, and Ireland. The most common side effects included headache, nausea, abdominal pain, menstrual pain, fatigue, and dizziness.
Women with known or suspected pregnancy or those who are breast-feeding shouldn't use ella, according to the FDA.
The drug is distributed by Watson Pharma Inc., based in Morristown, N.J.
The FDA has more about this approval.
Find in-depth content on major issues provided by leading companies in partnership with NursingCenter.com
BD Safety Beyond Needlestick Prevention Learning Center
Sponsored by BD Medical
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top